Mono Pharmacare Limited‘s primary activities revolve around marketing pharmaceutical products and acting as distributors for various pharmaceutical firms. Through collaborations with contract manufacturers, they facilitate the production of pharmaceutical items based on provided compositions, which are then marketed under their “DLS Export” brand.

Mono Pharmacare Limited has ties with 168 pharmaceutical firms and works with a network of 3,036 customers/vendors, including retail pharmacy stores and wholesalers. The promoter has more than one decade of expertise in the pharmaceutical industry.

Mono Pharmacare Limited’s portfolio includes products like Antibiotics, Antifungals, Anti-Cough Cold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac, and Diabetic & Cosmetics, among others.

Mono Pharmacare Limited underwent a significant development with the acquisition of “DLS Export,” a proprietorship firm initiated by promoter Panilam Lakhatariya. This smart move is desired to increase the company’s therapeutic product range. Also Mono Pharmacare Limited consolidated its operations by acquiring “Ahmedabad Medical Corporation (AMC)” and integrating “Supal Distributors LLP.” This integration simplified and optimized the company’s overall operations and resource management.

Mono Pharmacare Limited IPO Complete Details:

Mono Pharmacare Limited IPO Timetable:

Company Financial Details:

AS OF NOW, the GMP OF Mono Pharmacare Limited is Around 03 Rs.